脂康颗粒治疗非酒精性脂肪肝的临床研究

摘要
图/表
参考文献(21)
相关文章 (15)

全文: PDF (498 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察脂康颗粒治疗非酒精性脂肪肝的临床效果。方法将2014年10月～2015年10月河北医科大学第二医院中西医结合内科收治的80例非酒精性脂肪肝患者随机分为治疗组（42例）和对照组（38例）。对照组给予口服阿托伐他汀，治疗组给予口服阿托伐他汀和脂康颗粒，两组疗程均为12周。结果治疗组和对照组的治疗总有效率分别为92.86%和55.26%，差异有统计学意义（P ＜ 0.05）。两组治疗后三酰甘油、总胆固醇、谷草转氨酶、谷丙转氨酶水平均明显低于治疗前（P ＜ 0.05），且治疗组治疗后三酰甘油、总胆固醇、谷草转氨酶、谷丙转氨酶水平明显低于对照组，差异有统计学意义（P ＜ 0.05）。两组治疗后胰岛素抵抗指数、空腹血糖均明显低于治疗前（P ＜ 0.05），且治疗组治疗后胰岛素抵抗指数、空腹血糖明显低于对照组，差异有统计学意义（P ＜ 0.05）。两组治疗后眼花耳鸣、头胀、胸闷等自觉不适症状均较治疗前明显改善（P ＜ 0.05），且治疗组治疗后改善情况显著优于对照组（P ＜ 0.05）。结论脂康颗粒治疗非酒精性脂肪肝效果显著，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵秀敏李风学谷婧

关键词 ：非酒精性脂肪肝, 脂康颗粒, 临床效果

Abstract：Objective To observe the clinical curative effect of Zhikang Granules in the treatment of nonalcoholic fatty liver disease. Methods Eighty patients with nonalcoholic fatty liver disease admitted to Department of Integrated Chinese and Western Medicines, the Second Hospital of Hebei Medical University from October 2014 to October 2015 were randomly divided into the treatment group (42 cases) and the control group (38 cases). The control group was treated with Atorvastatin orally, while the treatment group was treated with Atorvastatin and Zhikang Granules orally. The course of the two groups was 12 weeks. Results The total effective rate of treatment group and control group was 92.86%, 55.26% respectively, the difference was statistically significant (P ＜ 0.05). After treatment, the levels of triacylglycerol, total cholesterol, glutamic oxalacetic transaminase, glutamic-pyruvic transaminase in the two groups were all lower than those before treatment (P ＜ 0.05), and the levels of triacylglycerol, total cholesterol, glutamic oxalacetic transaminase, glutamic-pyruvic transaminase in the treatment group after treatment were lower than those of control group, the differences were statistically significant (P ＜ 0.05). After treatment, the levels of insulin resistance index, fasting blood-glucose in the two groups were all lower than those before treatment (P ＜ 0.05), and the levels of insulin resistance index, fasting blood-glucose in the treatment group after treatment were lower than those of control group, the differences were statistically significant (P ＜ 0.05). After treatment, the subjective uncomfortable symptoms of giddiness and tinnitus, fullness in the head, chest distress in the two groups were significantly improved compared with those before treatment (P ＜ 0.05), and the improvement of treatment group was significantly better than that of control group (P ＜ 0.05). Conclusion The curative effect of Zhikang Granules in the treatment of nonalcoholic fatty liver disease is distinct, which is worthy of clinical promotion and application.

Key words： Non-alcoholic fatty liver disease Zhikang Granules Clinical effect

基金资助:河北省中医药管理局科研计划项目（2016047）。

引用本文:

赵秀敏李风学谷婧. 脂康颗粒治疗非酒精性脂肪肝的临床研究[J]. 中国医药导报, 2017, 14(18): 142-144.
ZHAO Xiumin LI Fengxue GU Jing. Clinical study of Zhikang Granules in the treatment of nonalcoholic fatty liver disease. 中国医药导报, 2017, 14(18): 142-144.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I18/142

[1] De Alwis NM，Day CP. Non-alcoholic fatty liver disease：Themist gradually clears [J]. J Hepatol，2008，48（Suppl 1）：S104-S112.
[2] Bedogni G，Miglioli L，Masutti F，et al. Prevalence of and risk factors for nonalcoholic fatty liver disease：the Dionysosnutrition and liver study [J]. Hepatology，2005，42（1）：44-52.
[3] Neuschwander-Tetri BA，Caldwell SH. Nonalcoholic steatohepatitis：summary of an AASLD Single Topic Conference [J]. Hepatology，2003，37（5）：1202-1219.
[4] Fan JG，Farrell GC. Epidemiology of non-alcoholic fatty liv-erdisease in China [J]. Hepatology，2009，50（1）：204-210.
[5] 张绵，胡亚兰，宋艳.ICU危重病人的心理分析及护理[J].中国实用神经疾病杂志，2010，13（8）：93.
[6] 姜杰瑜，陈程.中医“治未病”思想防治非酒精性脂肪肝研究进展[J].亚太传统医药，2015，11（20）：40-41.
[7] 王兆伟，吴乔，陈永红，等.中西医结合治疗非酒精性脂肪性肝病[J].西南军医，2015，26（2）：147-148.
[8] 陈灏珠，沈锡中，刘厚钰.实用内科学[M].北京：人民卫生出版社，2002.
[9] Schreuder TC，Verwer BJ，van Nieuwkerk CM，et al. Nonalcoholicfatty liver disease：An overview of current insights in pathogenesis，diagnosis and treatment [J]. World J Gastroenterol，2008，14（16）：2474-2486.
[10] Petta S，Muratore C，Craxì A，et al. Non-alcoholic fatty liver disease pathogenesis：the present and the future [J]. Digest Liver Dis，2009，41（9）：615-625.
[11] 裴强，王晓素，王宪波，等.非酒精性脂肪性肝炎发病机制的研究进展[J].临床肝胆病杂志，2008，24（4）：304-306.
[12] 崔香玉.决明子乙醇提取物对大鼠急性肝损伤的保护作用[J].延边大学医学学报，2009，29（4）：244-246.
[13] 楼陆军，罗洁霞，高云.山楂的化学成分和药理作用研究概述[J].中国药业，2014，23（3）：92-94.
[14] 赵秀敏.脂康颗粒联合阿托伐他汀治疗高脂血症的疗效及安全性评估[J].临床荟萃，2015，30（3）：268-271.
[15] Singh D，Das CJ，Baruah MP. Imaging of non alcoholic fatty liver disease：A road lesstravelled [J]. Indian J Endocricnol Merab，2013，17（6）：990-995.
[16] 何红梅，邵建国.非酒精性脂肪性肝病的中西医研究进展[J].南通大学学报：医学版，2014，34（3）：216-218.
[17] Day CP. Non-alcoholic fatty liver disease：a massive problem [J]. Clin Med，2011，11（2）：176-178.
[18] 卢丹.青少年非酒精性脂肪肝危险因素分析[J].现代医院，2016，16（3）：462-463.
[19] 尹娟，韩继武.非酒精性脂肪性肝病的发病机制及治疗进展[J].现代生物医药进展，2012，12（23）：4555-4559.
[20] 王伟毕，洪钟，潘金，等.肠道微生态失衡致非酒精性脂肪性肝病发病机制的研究进展[J].胃肠病学，2013，18（5）：317-320.
[21] 崔健娇，赵文霞.赵文霞教授治疗非酒精性脂肪性肝病经验总结[J].中国中医药现代远程教育，2014，12（22）：26-27.